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0022-2836 © 2012 Elsevier Ltd. Open accThemalarial aminopeptidases have emerged as promising new drug targets
for the development of novel antimalarial drugs. The M18AAP of
Plasmodium falciparum malaria is a metallo-aminopeptidase that we show
demonstrates a highly restricted speciﬁcity for peptides with an N-terminal
Glu or Asp residue. Thus, the enzyme may function alongside other
aminopeptidases in effecting the complete degradation or turnover of
proteins, such as host hemoglobin, which provides a free amino acid pool
for the growing parasite. Inhibition of PfM18AAP's function using antisense
RNA is detrimental to the intra-erythrocytic malaria parasite and, hence, it
has been proposed as a potential novel drug target. We report the X-ray
crystal structure of the PfM18AAP aminopeptidase and reveal its complex
dodecameric assembly arranged via dimer and trimer units that interact to
form a large tetrahedron shape that completely encloses the 12 active sites
within a central cavity. The four entry points to the catalytic lumen are each
guarded by 12 large ﬂexible loops that could control substrate entry into theess: Sheena.McGowan@monash.edu.
authors.
falciparum; Hb, hemoglobin; DAP, diaminopropionic acid; pNA, p‐nitroaniline; ACC,
; DNPEP, human aspartyl aminopeptidase; NCS, noncrystallographic symmetry.
ess under CC BY-NC-ND license.
‡http://plasmodb.org/plasmo/
496 Crystal Structure and Specificity of PfM18AAPcatalytic sites. PfM18AAP thus resembles a proteasomal-like machine with
multiple active sites able to degrade peptide substrates that enter the central
lumen. The Plasmodium enzyme shows signiﬁcant structural differences
around the active site when compared to recently determined structures of
its mammalian and human homologs, which provides a platform from
which a rational approach to inhibitor design of new malaria-speciﬁc drugs
can begin.© 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.Introduction
Malaria remains a global health issue and ac-
counts for as many as 1 million deaths each year.1
Signiﬁcant progress has been made with respect to
the development of a malaria vaccine, although the
limited efﬁcacy of these and the challenges of
widespread vaccination programs dictate that con-
trol of malaria will continue to depend on chemo-
therapeutic intervention.2,3 The prevention and
treatment of malaria caused by infection with the
parasite Plasmodium falciparum (Pf) are becoming
increasingly complicated due to the spread of drug-
resistant parasites.4,5 The development of next‐
generation antimalarial agents is a matter of urgency
and depends on identifying drugs with new modes
and/or targets of action.1,6
The Pf parasite has a complex life cycle that
requires both human and mosquito hosts.7 The
asexual intra-erythrocytic stage of Pf infection is
responsible for all of the clinical symptoms of
malaria. Intra-erythrocytic malaria parasites avidly
consume the erythrocyte hemoglobin (Hb), exploit-
ing it as a source of amino acids for incorporation
into its own proteins. An acidic organelle inside
the parasite, the digestive vacuole, is the primary
site of Hb proteolysis where the action of a
number of endopeptidases, a dipeptidase, and
aminopeptidases reduce the molecule to peptides
and dipeptides, and possibly some free amino
acids.7–9 However, it is believed that the majority
of the Hb peptides are exported from the vacuole
into the cytoplasm of the cell where several
Plasmodium metallo-aminopeptidases act in concert
to convert the Hb peptides into individual amino
acids.
Nine metallo-aminopeptidases have been identi-
ﬁed in the Pf genome‡ (see Ref. 10). Four of these
are methionine aminopeptidases that presumably
have a housekeeping role and may function in the
removal of the initiator methionine from newly
synthesized polypeptides. The other ﬁve enzymes
comprise a prolyl iminopeptidase (or post-prolyl
aminopeptidase), a prolyl aminopeptidase, a leu-
cine aminopeptidase (PfA-M17), an alanine amino-peptidase (PfA-M1), and the PfM18AAP
aminopeptidase. Given the restricted speciﬁcities
of each of these enzymes for particular N-terminal
amino acids, it is thought that they act in concert
to facilitate Hb catabolism. Consistent with this
idea, both PfA-M1 and PfA-M17 have been shown
to be essential for the survival of the parasite.11
The PfA-M1 enzyme is indeed involved in Hb
degradation, while the PfA-M17 may have addi-
tional function since speciﬁc inhibition of its
activity in Pf parasite cultures caused growth
retardation early in the intra-erythrocytic life
cycle before Hb digestion is initiated.12 We have
previously determined the X-ray crystal structures
of both PfA-M1 and PfA-M17.13,14
PfM18AAP is an ~65‐kDa aminopeptidase of the
M18 family of metalloproteases.15 The PfM18AAP
gene is present in single copy on the Pf genome
and the protease is expressed in the parasite
cytoplasm and also exported to the space between
the parasite and host cell, known as the para-
sitophorous vacuole.16 Gene disruption/truncation
experiments of PfM18AAP indicated that the
enzyme was dispensible for blood-stage replication
but had an associated ﬁtness cost to the parasite.17
Anti-sense RNA knockdown of PfM18AAP, how-
ever, resulted in parasite growth abnormalities,
vascularization, and cellular damage.16 The cellu-
lar localization and role in growth and develop-
ment thus indicate that the enzyme may have
additional functions in addition to Hb digestion.
Lauterbach and Coetzer showed that PfM18AAP
binds to erythrocyte spectrin and other membrane
proteins and suggested that the enzyme could play
a role in the release of the parasite from the host
erythrocyte.18 Accordingly, from a perspective of
new antimalarial drug development, PfM18AAP,
along with PfA-M1 and PfA-M17, remains a
protein of high interest.19
TheM18 aminopeptidases are zincmetalloenzymes
that exist as high‐molecular‐weight complexes; pre-
vious gel‐ﬁltration analyses of recombinant and
native PfM18AAP suggested that the enzyme assem-
bly was octameric. PfM18AAP exhibits optimal
activity at a neutral pH, and studies using chelation
agents have shown that altering the type of metal ion
in the active site can increase catalytic efﬁciency but
does not affect binding of the substrate.16 Here, we
present the X-ray crystal structure of PfM18AAP and
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aspartyl aminopeptidase (DNPEP)/M18 aminopep-
tidase family. Like the bovine and human
M18AAP,20 PfM18AAP forms a complex homo-
dodecameric tetrahedron quarternary structure but
exhibits subtle differences in structure that could be
exploited in speciﬁc inhibitor design.Results
Purification of active recombinant PfM18AAP
from Escherichia coli requires chaperonin
As reported by Teuscher et al., recombinant
PfM18AAP had been successfully expressed and
puriﬁed from insect cells using a synthetic
construct.16 To improve the yield of protein for
crystallography studies, we constructed a new DNA
construct for expression in E. coli. Recombinant
PfM18AAP was produced as an N-terminal hexahis-
tidine fusion protein and puriﬁed using sequential
Ni-NTA afﬁnity and size‐exclusion chromatogra-
phy. Gel‐ﬁltration chromatograms consisted of a
single peak that was clearly in the void volume. This
initial material had no enzymatic activity. SDS-
PAGE analysis of the gel‐ﬁltration peak showed
two protein bands at ~65 kDa. N-terminal sequenc-
ing of these two protein species identiﬁed that the
dominant species was chaperonin GroEL (RefSeq
ZP_06938783.1). To remove the chaperone protein
from our puriﬁed PfM18AAP, we added a dissoci-
ation step to our puriﬁcation protocol. Post-dissoci-
ation, the repuriﬁed protein was enzymatically
active against the simple chromogenic substrate L‐
glutamic acid γ-(4-nitroanilide) [L‐Glu-p‐nitroaniline
(pNA)] and was positively identiﬁed as PfM18AAP
by N-terminal sequencing.
PfM18AAP forms a dodecamer in solution
Gel ﬁltration of the puriﬁed PfM18AAP alone
showed that the protein was still retained in the void
volume of an S200 10/300 column, indicating that
the soluble protein was forming a high‐molecular‐
mass complex. Previous studies had employed
analytical gel ﬁltration to estimate the molecular
mass of the PfM18AAP and showed that it behaved
as an octamer in solution (~560 kDa).16 To deﬁni-
tively identify the size of the PfM18AAP oligomer in
aqueous solution, sedimentation velocity studies
were employed in the analytical ultracentrifuge at
initial protein concentrations ranging from 0.1 mg/
ml to 1.0 mg/ml. Similar data were obtained at all
concentrations studied. As an example, the absor-
bance versus radial position proﬁles at different time
points are shown in Fig. 1a (open symbols) for
PfM18AAP at 0.5 mg/ml. These data were subse-quently ﬁtted to a continuous sedimentation coefﬁ-
cient [c(s)] distribution model (Fig. 1b) and a
continuous mass [c(M)] distribution model
(Fig. 1c). Both models yielded excellent ﬁts, as
demonstrated by the random distribution of re-
siduals (Fig. 1b and c, top panels) and low (b0.01)
rmsd values (Table 1). The data show that the
protein predominantly exists as a 20.4±1.5 S
(Svedberg) species with an apparent molar mass of
722±100 kDa, consistent with a dodecameric spe-
cies (Fig. 1c; Table 1). The frictional coefﬁcient (f/f0)
of the dodecamer is calculated to be 1.51 (Table 1),
which indicates that the oligomer is nonspherical
or asymmetric in shape. There are also small
amounts of other species observed with sedimenta-
tion coefﬁcients of ~6 S, ~10 S, ~14 S, and ~30 S
(corresponding to estimated molecular masses of
~130 kDa, ~260 kDa, ~400 kDa, and 1300 kDa, re-
spectively). These species are likely to represent other
oligomeric forms of PfM18AAP, potentially dimers,
tetramers, hexamers, and octadecamers. Similar re-
sults are obtained at initial protein concentrations of
0.1 mg/ml and 1.0 mg/ml (Supplementary Fig. 1),
thus indicating that the dodecamer of PfM18AAP is
stable over the 10-fold concentration range.
Biochemical characterization and primary
specificity of PfM18AAP
Recombinant PfM18AAP isolated from insect cells
has been characterized previously. To ensure that our
E. colimaterial retained similar enzymatic properties,
we investigated the enzyme activity of the puriﬁed
protein prior to crystallization. The presence of
metal ions has been shown to enhance and/or
inhibit the activity of M18 family members;16,20,24
hence, to determine the optimum assay conditions,
we tested the enzyme efﬁciency against a variety of
metal cations. We supplemented the activity assay
buffer with different concentrations of various
cations and assayed the activity of a ﬁxed con-
centration of PfM18AAP against L-Glu-pNA. The
results showed that Co(II) and Mn(II) enhanced
activity while Zn(II), Mg(II), and Ni(II) had little
effect (Fig. 2). At high concentrations (N1 mM),
Zn(II), Mg(II), and Ni(II) were found to be
inhibitory to activity (Fig. 2). Given this conﬁrma-
tion, we chose to supplement our assay buffers
with 1 mM CoCl2 to enhance the in vitro activity of
PfM18AAP. Puriﬁed PfM18AAP efﬁciently cleaved
L‐Glu-pNA with kcat/Km values of 2265 M
− 1 s− 1,
consistent with published data.16
Todetermine the substrate speciﬁcity ofPfM18AAP,
we screened a recently developed ﬂuorogenic
substrate library of 19 natural and 41 nonnatural
amino acids to obtain a substrate ﬁngerprint for the
enzyme.25,26 The results conﬁrm a highly restricted
selectivity with enzyme activity observed only in the
presence of the natural amino acids Glu, Asp, and
Fig. 1. Sedimentation velocity analysis of 0.5 mg/ml PfM18AAP. (a) Absorbance versus radial position proﬁles of
PfM18AAP at different time points with the raw data shown as open symbols overlaid with the c(s) distribution best-ﬁt
(continuous lines). (b) Continuous size, c(s), distribution is plotted as a function of standardized sedimentation coefﬁcient
(s20,w) for PfM18AAP generated using 500 species over a sedimentation coefﬁcient range of 0.01 S to 50 S and at a
conﬁdence level (F ratio)=0.95. Top: Residuals for the c(s) distribution best ﬁts plotted as a function of radial position (cm).
(c) Continuous mass, c(M), distribution plotted as a function of molecular mass for PfM18AAP using 500 species ranging
from 2 kDa to 2000 kDa and at a conﬁdence level (F ratio)=0.95. Top: Residuals for the c(M) distribution best ﬁts plotted as
a function of radial position (cm). The c(s) and c(M) distribution analyses were performed using the program SEDFIT21–23,
which is available at www.analyticalultracentrifugation.com.
Table 1. Hydrodynamic properties of PfM18AAP at
0.5 mg/ml, calculated from sedimentation velocity analyses
s20,w
a (S) Mr
b (Da) Mc (kDa) f/f0
d
20.4±1.5 65,705 722±100 1.51
a Standardized sedimentation coefﬁcient taken from the
ordinate maximum of the c(s) distribution (Fig. 1b).
b Relative monomeric molecular mass (Mr) determined from
the amino acid sequence.
c Apparent molar mass (M) taken from the ordinate maximum
of the c(M) distribution (Fig. 1c).
d Frictional ratio calculated using the v method21 employing
the experimentally determined s20,w and theoretical molecular
mass of the PfM18AAP dodecamer (i.e., 788,460 Da).
498 Crystal Structure and Specificity of PfM18AAPAsn and the nonnatural amino acid 2,3-diaminopro-
pionic acid (DAP) (Fig. 2). Subsequently, we deter-
mined the kinetic parameters for each substrate
(Table 2) and show that the enzyme has no
signiﬁcant preference between a P1 Glu or Asp
residue. Interestingly, a P1 Asn residue had an
equivalentKmvalue to the other natural amino acids;
however, the general rate constant indicates that
PfM18AAP turns this substrate over 10 times slower
than either Glu/Asp. The nonnatural amino acid
DAP was preferred over the natural Asn residue
with a tighter Km (~7× lower than any of the natural
amino acids) and a faster rate constant (Table 2).
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Fig. 2. Effect of various cations on activity of PfM18AAP and individual preference in S1 pocket of PfM18AAP toward
natural and nonnatural amino acid substrates. (a) Co2+, Zn2+, Mg2+, Mn2+, and Ni2+ (0.01–100 mM)were incubated with
125 nM enzyme before the addition of substrate L‐Glu-pNA (100 μM). (b) Screening of the 60-membered natural and
nonnatural amino acid library. Enzyme activity was monitored via ﬂuorescence at an excitation wavelength of 355 nm
and an emission wavelength of 460 nm. The x-axis represents the abbreviated amino acid names. The y-axis represents the
average relative activity expressed as a percentage of the best amino acid.
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The structure of PfM18AAP was solved by molec-
ular replacement andwas reﬁned to 2.6 Å and anRfree
of 19.6% (Table 3; Fig. 3). The initial molecularTable 2. Kinetic parameters of speciﬁc PfM18AAP ﬂuorogeni
Substrate P1 side chain kcat/K
#3—NH2-Asn-ACC 4
#4—NH2-Asp-ACC 36
#6—NH2-Glu-ACC 39
#23—NH2-Dap-ACC 9replacement solution was completed manually
using Coot27 and AutoBuster.28 The ﬁnal model
had 4 molecules within the asymmetric unit, along
with 8 zinc ions and 444 solvent molecules. Applica-
tion of the space group symmetry matrices generatedc substrates
m (M
−1 s−1) kcat (s
−1) Km (μM)
5.5±3.47 0.028±0.002 625.5±47.2
0.1±28.5 0.203±0.017 563.7±48.1
7.5±30.5 0.200±0.014 503.1±33.6
6.6±8.5 0.070±0.008 72.46±9.43
Fig. 3. The 2.6‐Å X-ray crystal structure of PfM18AAP.
The cartoon model of the 12 PfM18AAP monomers in their
dodecameric arrangement.Monomers are colored by chains
found in the asymmetric unitA (red), B (Blue), C (green), and
D (yellow, at the back of the molecule in this view). The
application of space group symmetrymatrices generates the
dodecamer with three copies of each chain (Chains D, D1
and D2 are at the back of the molecule in this view).
Table 3. Data collection and reﬁnement statistics
PfM18AAP
Data collection
Space group P213
Cell dimensions (Å) a=b=c=200.38 Å, β=90.0°
Resolution (Å) 100.39–2.60 (2.74–2.60)
Total number of observations 789,865
Number of unique observations 82,063
Multiplicity 9.6 (6.8)
Data completeness (%) 100.0 (99.9)
〈I/σI〉 8.0 (1.5)
Rpim (%)
a 8.3 (58.0)
Structure reﬁnement
Non‐hydrogen atoms
Protein 15,002
Solvent 444
Rfree (%) 19.6
Rcryst (%) 15.9
rmsd from ideality
Bond lengths (Å) 0.009
Bond angles (°) 1.14
Ramachandran plot
Favored (%) 97.9
Allowed (%) 100.0
B‐factors (Å2)
Mean main chain 41.2
Mean side chain 46.3
Mean water molecule 38.5
rmsd bonded Bs
Main chain 2.24
Side chain 5.04
MolProbity score 1.78 (99th percentile
(N=6237, 2.60 Å±0.25 Å)
Values in parentheses refer to the highest‐resolution shell.
a Agreement between intensities of repeated measurements of
the same reﬂections can be deﬁned as: ∑(Ih,i− 〈Ih〉)/∑ Ih,i, where
Ih,i are individual values and 〈Ih〉 is the mean value of the intensity
of reﬂection h.
500 Crystal Structure and Specificity of PfM18AAPthe unit cell that contained four complete dodecamers
in a tetrahedral arrangement (Fig. 3). The quality of
themodelwas evaluated using theMolProbity server
(Table 3 and Refs. 29,30). Residues 166–169, 197–272,
and 348–363 were omitted from the model due to
absent electron density. Superposition of monomers
A, B, C, and D reveals that they are essentially
identical (average rmsd, 0.54 Å over 468 Cα atoms).
Thus, unless stated otherwise, all structural analysis is
conﬁned to monomer A and numbering is as
per PfM18AAP.
The overall structure of PfM18AAP monomer
consists of two domains, a catalytic domain (residues
1–92 and 307–577) and a regulatory domain (resi-
dues 92–306) that together adopt a canonical M18
aminopeptidase fold20 (Fig. 4a). The regulatory
domain comprises two three-stranded antiparallel
β-sheets and two helices. The arrangement of the β-
sheets around helical residues 279–289 appears to
interrupt what would otherwise be a central β-sheet
through the domain. Extensive loop structures are
noted in this domain (Fig. 4a). These loop regions
contain two small helical turns and regions of
disorder in our model, indicating the ﬂexibility of
this region of the protein. In each monomer present
in the asymmetric unit, we noted that there was a
break in connected density of the loop comprising
residues 163–169 and that residues 197–272 also had
no visible density (Fig. 4a).The catalytic domain (residues 1–91 and 307–577)
comprises a central seven-stranded β-sheet ﬂanked
on both sides by 10α-helices. A second four-stranded
antiparallel β-sheet occupies the space at the top of
one side of theαβα arrangement (Fig. 4a). The helices
form a funnel shape to the bottom of the molecule
while the top of the domain remains largely open and
unstructured with loop regions. The loop regions at
the top of the domain, combined with residues from
the central sheet, form the active‐site cleft of each
monomer. The active site of each monomer con-
tained two zinc ions that are well coordinated by
highly conserved residues His87, Asp325, Glu381,
Asp435, andHis535 (Fig. 4b; Supplementary Table 1).
The active site of each monomer is a small closed
cavity that has a small entrance (diameter, 5.6 Å) lined
by residues Glu380, Glu381, Gly509, Ser510, and
His535. The His161 loop residues of the dimeric
partner (see below) further restrict the size of the
active site and access to the zinc ions (Fig. 4c). Past the
cations is a small substrate binding pocket lined by
residues Asp435, Met436, His438, Lys463, Tyr470,
Phe500, Thr511, and Met534.
Ile273 
Lys196 
(a) (b)
(c)
Arg165 
Phe170 
Asn364 
His347 
His535 
Asp325 
His87 
Glu381 
Asp435 
Zn 
Zn 
Zn 
Zn 
Lys463 
His161 
Fig. 4. Cartoon model of the PfM18AAP monomer and active site. (a) The PfM18AAP monomer with the regulatory
domain (residues 92–306) shown in red and the catalytic domain (residues 1–91 and 307–577) shown in green. The zinc
ions are shown as black spheres and zinc binding residues are shown. The last ordered residues at gaps in the model are
indicated. (b) The zinc ion coordination in the active site of PfM18AAPwith carbon atoms of zinc binding residues shown
in gray and zinc as black spheres. Metallo-bonds are shown as black broken lines. (c) The active‐site architecture restricts
enzyme speciﬁcity. In this view, the electrostatic potential of Chain D is shown and a cartoon model of Chain C (green)
and His161 is shown in stick. Chains A and B are excluded from view for clarity. The active‐site zinc ions of Chain D are
shown as black spheres and indicated. The Lys463 residue at the base of the S1 pocket is indicated.
501Crystal Structure and Specificity of PfM18AAPThe architecture of the active site immediately
identiﬁes the basis of the highly restricted substrate
speciﬁcity of PfM18AAP for Glu, Asp, and Asn. The
S1 pocket is small and buried immediately behind
the zinc ions (Fig. 4c). It is lined predominantly with
polar residues, and Lys463, which sits at the very
base of this pocket (Fig. 4c), presumably provides
the counter binding partner for the Glu/Asp sub-
strates. A similar Lys residue is observed at the base
of the homologous bovine M18AAP and is sug-
gested to be involved in substrate binding.20
The biological assembly of PfM18AAP
The biological assembly of the PfM18AAP is a
dodecamer that forms a tetrahedron shape (Fig. 3).
The assembly comprises both dimers and trimers of
PfM18AAP. The four molecules in our asymmetricunit form one dimeric and one trimeric interaction.
The dimer interaction (Chains C and D) is
dominated by interactions of the two regulatory
domains and the smaller four-stranded sheet of the
catalytic domain (Fig. 5a). The dimer interface is
extensive and has a total of 57 H-bonds and four
salt bridges (Supplementary Table 1) that buries a
surface area of 3693 Å2. As described for the
mammalian enzyme, we also noted that the
extended loop formed by residues 155–180 reaches
into the active site of the dimer partner and
contributes His161 to the catalytic center (Figs. 5a
and 4c). Like the bovine and human M18 amino-
peptidases, this residue does not contribute directly
to zinc binding (distance is N4.5 Å) although it has
been shown to be essential for functional activity of
the enzyme.31 Interestingly, residues 165–170 are
also located in this well-coordinated loop despite
His161 
(a) (b)
Fig. 5. The PfM18AAP enzyme has dimeric and trimeric assemblies. The asymmetric unit of the PfM18AAP X-ray
crystal structure has four monomers present. Within these molecules, (a) a dimer is formed by Chains C (green) and D
(yellow), with the dimeric partner contributing His161 to the active site (inset). (b) The trimer is formed by Chains A (red),
B (blue), and C (green).
Fig. 6. The molecular surface of PfM18AAP shows
active‐site cavity entry pores. The dodecamer is colored as
in Fig. 3. The last ordered residues (195 and 272) at the
edge of the loop insertion are located at the periphery of
the entrance tunnels and shown as magenta spheres.
502 Crystal Structure and Specificity of PfM18AAPthe fact that these residues have no visible electron
density in our structure, which is in direct contrast
to the bovine and human enzymes (3VAT and
3L6S, respectively). In these latter enzymes, the
sequence of this loop is conserved, while in the
Plasmodium enzyme, it contains a unique sequence
that includes charged and polar residues (Supple-
mentary Fig. 2).
Three catalytic domains interact to form the cone-
shaped trimer of PfM18AAP (Chains A, B, and C)
(Fig. 5b). The interactions of each monomer are
predominantly mediated by the helices of each
catalytic domain with the regulatory domain acting
like a packing buffer between each catalytic domain.
The interface between each chain is composed of
31 H-bonds and 10 salt bridges (Supplementary
Table 1) and buries a surface area of 2144 Å2. The
three active sites are located in an equilateral
triangle of ~33 Å from each other. The PfM18AAP
trimers interact with each other to form the ﬁnal
biological dodecamer. These interactions are pre-
dominantly mediated by the regulatory domain of
each monomer. The interior active‐site cavity of
PfM18AAP is composed therefore of four trimeric
cones, each with their three active sites, and has a
buried surface area of 36,226.7 Å2. The dodecamer
503Crystal Structure and Specificity of PfM18AAPhas four large “pores”, measuring ~23 Å in diame-
ter, which provide a tunnel to the inside of the active‐
site cavity (Fig. 6). Interestingly, the disordered loop
(residues 197–272) of the symmetry-related chain
(e.g., A, A1 and A2) shows that this loop would be
located directly over the entrance of these large
pores. The last ordered residue in the electron
density clearly shows that the loops extend out
from the periphery of the pore formation (Fig. 6).
From this location, we propose that these loops
would form a barrier to active‐site entry, acting to
regulate and control the enzyme's function. Second-
ly, given the size of this loop (N70 residues), we
suggest that this extreme ﬂexibility is the reason
that chaperonin was required for protein expression
and puriﬁcation.
Structural and sequence comparison of
PfM18AAP with DNPEP and bacterial homologs
The DNPEP family is characterized by a canonical
fold that is shared in all structures solved to date (four
bacterial: 2GLF, 2GLJ, 1YFE, and 2IJZ; one mamma-
lian: 3VAT;20 and one human: 3L6S). The parasite
PfM18AAP comprises the same overall monomeric
and quarternary structure as the enzyme family;
however, the malaria enzyme exhibits unique
changes in the loop regions of the regulatory domain
and within the helices of the catalytic domain. The
predominant difference between the PfM18AAP and
other characterized enzymes to date is the presence of
two large insertions, one in the regulatory domain
(residues 195–260) and another in the catalytic
domain (residues 346–363) (Supplementary Fig. 2).
The large insertion in the regulatory domain is
unique to Pf and is not present in other Plasmodium
homologs. In both the human and PfM18AAP
structures, the last conserved residue before the
insertion (residues 195) is the last ordered residue
before a break in connective density. The structure
of the human enzyme is missing the next 21 residues
while the PfM18AAP enzyme is missing density for
the next 76 amino acids. The mammalian enzyme
(3VAT) has an equivalent break in connective
density.20 The bacterial enzymes vary in this trend
and show a loss of the preceding helix but
connective density throughout this region. The
exception appears to be the Pseudomonas aeruginosa
(2IJZ) enzyme that shows the same loss of the helix
but has connective density.
The second insertion is located in the catalytic
domain and is also disordered in the X-ray crystal
structure. The last ordered residues are His347 and
Asn264, which are located at the bottom of the
molecule. They are not located in a position that
would interfere with assembly of the trimer. The
mammalian and human enzymes both show or-
dered connective density in this region.Besides the sequence insertion, the catalytic
domain of PfM18AAP shows signiﬁcant movement
of helices, in particular residues 393–414 that form a
long helix at the bottom of the catalytic domain and
undergo a 90° bend at residue 408 to accommodate a
stretch of charged residues. In the trimeric structure,
the helical bend in the three helices effectively closes
the bottom of the trimer structure. The equivalent
helix in the human and mammalian enzymes is not
bent and the helix terminates at the position of the
bend in PfM18AAP.Discussion
Intracellular proteolysis requires very intricate
biochemical machinery and is subject to spatial
and temporal control in order to prevent the damage
of proteins not destined for destruction. Some of
these high-molecular‐weight protease enzymes are
self-compartmentalized; that is, they form cellular
subcompartments through self-association and en-
close inner cavities that harbor the proteolytic active
sites.32 The inner active‐site cavities localize multi-
ple active sites, allowing proteolysis to occur
efﬁciently. By restricting access to the cavity, the
active sites are only accessible to unfolded poly-
peptides or peptides, and in this way, cytoplasmic
proteins are protected from unwanted cleavage.
Examples of this are cellular proteasomes and,
increasingly, the aminopeptidases.33,34
Aminopeptidases constitute a diverse set of
protease enzymes with essential roles in cell
maintenance, growth and development, defense,
memory, tumor growth and metastasis, and anti-
gen presentation. In Pf, a major malaria parasite of
humans, the aminopeptidases are hypothesized to
be involved in the catabolism of host Hb, a process
essential for parasite survival. The Pf aminopepti-
dases PfA-M1 and PfA-M17 are validated drug
targets; inhibitors have been shown to kill the
parasite in culture and in vivo.11,13,14 In recent
years, we have undertaken an extensive structural
and functional characterization of these enzymes in
an effort to understand their mechanism and
speciﬁcity.13,14,26,35,36 Now, we can further this
understanding by the comparison of the amino-
peptidase PfM18AAP with these two enzymes with
which it may function in concert. The PfA-M1
enzyme has a broad substrate speciﬁcity in
comparison to PfA-M17 that is restricted to
hydrophobic amino acids,13,26 although the two
enzymes share a predominant preference for Leu,
followed by Met, Trp, and Phe.26 The PfM18AAP
enzyme can efﬁciently cleave Glu and Asp and
shows limited activity against Asn. The charge of
the S1 pocket of PfM18AAP is dominated by the
Lys463 residue, providing a negative charge to the
small space and accounts for the afﬁnity of both
504 Crystal Structure and Specificity of PfM18AAPGlu and Asp (Fig. 4c). The limited activity toward
Asn and even the nonnatural DAP residue is
presumably the result of the smaller size of these
two residues as Gln, which has a similar charge to
Asn but is of longer length, was not cleaved at all
by the enzyme. Taken together, the speciﬁcities of
the three enzymes, PfA-M1, PfA-M17, and
PfM18AAP, are capable of working in concert to
turnover peptides with any P1 residue except Pro
(this residue may have its own specialized enzyme,
prolyl aminopeptidase).
The 2.6‐Å X-ray crystal structure of PfM18AAP
reveals that the enzyme adopts an M18 aminopep-
tidase fold, forming a complex dodecameric biolog-
ical assembly. The tetrahedron‐shaped unit forms an
active‐site inner cavity that houses 12 active sites,
each with a di-zinc metal center. It is interesting to
make a parallel with the PfA-M17, which exhibits a
highly restricted selectivity for leucine amino acids
and exists as a homo-hexameric enzyme with each
di-zinc active site surrounding a central cavity. Each
site is also gated by a ﬂexible loop, which may
regulate substrate entry. Perhaps both enzymes are
associated with a subcompartmentalized district of
the cytoplasm where peptides are distributed and
sorted for processing to free amino acids.
Studies on the mammalian enzyme show that the
cations present in the active site can be altered
depending on the concentration of metals in the
environment. Enzymatic analysis of our PfM18AAP
shows similar results with optimal enzyme activity
in the presence of Cobalt(II) ions. The di-zinc active
site immediately reveals the reason for the highly
restricted substrate speciﬁcity with the small narrow
cavity for the substrate binding pocket. The active
site is formed by the contribution of a loop from the
dimeric partner molecule. The coordination of this
loop provides a functionally conserved histidine
residue into the active site of its partner in the dimer.
Although not directly contributing to zinc binding,
this residue has been shown to be essential for the
functional activity of the enzyme.31 In PfM18AAP,
we noted that this loop had ﬂexibility in all four
chains in our model, implying ﬂexibility throughout
this region. This is in contrast to the mammalian and
human enzymes that show a connected loop
containing a small helical turn. This variation in
the Plasmodium enzyme may provide substrate
speciﬁcity or act as a “substrate clamp” when
substrate is present (Supplementary Fig. 3).
PfM18AAP has a large insertion (residues 195–
273) in the regulatory domain of the protein that is
unique to Pf malaria. Studies show that this region
of PfM18AAP is capable of binding to erythrocyte
spectrin and other membrane proteins and suggests
that PfM18AAP may have functional roles in the
parasite that are additional to Hb digestion.18
Within this large insertion, a putative “spectrin
binding domain” has been identiﬁed.18 It is sug-gested that given PfM18AAP is expressed by mature
schizonts prior to cell rupture, the enzyme could
play a role in the release of the parasite from the host
erythrocyte by unlocking its cytoskeleton. In
PfM18AAP and human/mammalian homologs,
this region of the protein shows considerable
ﬂexibility and cannot be modeled in structures.
Interestingly, the last ordered residue in electron
density or the “stumps” of this loop/insertion
shows that this region would clearly be solvent
exposed and is located at the periphery of large
“pores” that access the buried active‐site cavities
(~23 Å in diameter, Fig. 6). We suggest that the
access to this interior cavity is tightly controlled and
must occur through local areas of ﬂexibility—
predominantly thought to be the loops of the
regulatory domain.
The PfM18AAP adopts the canonical M18 amino-
peptidase fold; however, it possesses unique fea-
tures that distinguish it from other members of the
family. These differences are predominantly found
in the loop and surface‐exposed regions of the
protein, creating a unique enzyme designed for its
role in the Plasmodium. Studies have shown that
interruption of PfM18AAP activity has a ﬁtness cost
to the parasite.17 Speciﬁc potent inhibitors of
PfM18AAP have not been identiﬁed; thus, it has
not yet been possible to determine if PfM18AAP
represents a novel drug target. Nevertheless, com-
pounds designed to inhibit PfM18AAP may possess
novel antimalarial properties that when combined
with other agents provide a new avenue for
chemotherapeutic control of malaria. The common
catalytic core of the Plasmodium aminopeptidases
PfA-M1, PfA-M17, and PfM18AAP makes them
attractive targets for the rational design of antima-
larial compounds that target all three enzymes.Materials and Methods
Purification and molecular analysis of recombinant
PfM18AAP
The full‐length gene sequence PF11570cwas synthesized
using codons optimized for gene expression in E. coli
(DNA2.0).Unique EcoRI andHindIII siteswere introduced
at the 5′ and 3′ ends, respectively. The synthesized gene
was cloned into the bacterial expression vector pRSET-B,
introducing an in-frame N-terminal hexahistidine tag to
the construct. The E. coli expression construct containing
the PfM18AAP gene was veriﬁed by DNA sequencing.
This construct was used to overexpress the PfM18AAP
in BL21(C41) cells grown in AutoInduction Media. Over-
expressed cells were lysed in 50 mM phosphate-buffered
saline, pH 8.0, 300 mM NaCl, and 5% glycerol. Prelimi-
nary puriﬁcation of the hexahistidine‐tagged PfM18AAP
was puriﬁed using a two-step puriﬁcation process of Ni-
NTA agarose column followed by size‐exclusion chroma-
tography on a Superdex 200 16/60 using an AKTAxpress
505Crystal Structure and Specificity of PfM18AAPhigh‐throughput chromatography system§. The enzyme
co-puriﬁed with chaperonin. Removal of the chaperonin
was achieved by rebinding the co-puriﬁed proteins to Ni-
NTA agarose column and then by extensive washing in
dissociation buffer (50 mM Hepes, pH 8.0, 300 mM NaCl,
5% glycerol, 150 mM KCl, 10 mM MgCl2, and 10 mM
ATP). Post-dissociation, the column was returned to
50 mM Hepes, pH 8.0, 300 mM NaCl, and 5% glycerol,
and puriﬁed PfM18AAP was eluted by the addition of
500 mM imidazole. Puriﬁed PfM18AAP was desalted and
concentrated for use. Biochemical analysis indicated that
kinetic parameters (kcat, Km, kcat/Km) of material puriﬁed
and used in subsequent crystallization trials were equiv-
alent to the recombinant material puriﬁed from insect cells
as previously published.16
Analytical ultracentrifugation
Sedimentation velocity experiments were conducted in
a Beckman model XL-I analytical ultracentrifuge at a
temperature of 20 °C. A total of 380 μl of PfM18AAP at
0.1 mg/ml, 0.5 mg/ml, and 1.0 mg/ml and 400 μl of
reference solution [50 mM Hepes, 300 mM NaCl, and 5%
(v/v) glycerol, pH 8.0] were loaded into conventional
double‐sector sapphire cells and mounted in a Beckman
4-hole An-60 Ti rotor. Samples were centrifuged at a rotor
speed of 25,000 rpm, and the data were collected
continuously at a single wavelength (280 nm), using a
step size of 0.003 cm without averaging. Solvent density
(1.0224 g/ml at 20 °C) and viscosity (1.159 cp at 20°), as
well as estimates of the partial speciﬁc volume (0.73 ml/g
at 20 °C) and hydration estimate (0.393 g/g), were
computed using the program SEDNTERP.37 Sedimenta-
tion velocity data at multiple time points were ﬁtted to a
continuous sedimentation coefﬁcient [c(s)] distribution
and a continuous mass [c(M)] distribution model21–23
using the program SEDFIT∥.
Enzymatic analysis
Aminopeptidase activity was determined by measuring
the hydrolysis of pNA from the chromogenic substrate L‐
glutamic acid γ-(4-nitroanilide) (L-Glu-pNA) (Sigma
#G1135). Reactions were carried out in 96-well microtiter
plates (200 ml total volume, 60 min, 37 °C) using a
spectroﬂuorimeter (BMG LabTech Optima) with excita-
tion at 405 nm. Enzyme was ﬁrst added to 50 mM Tris–
HCl, pH 7.5, supplemented with 1 mM CoCl2 before the
addition of 100 μM L‐Glu-pNA. Initial rates were obtained
at 37 °C over a range of substrate concentrations spanning
Km (32–2000 μM) and at ﬁxed enzyme concentrations in
50 mM Tris–HCl, pH 7.5, supplemented with 1 mM
CoCl2. Experiments to characterize the metal dependency
of the PfM18AAP were carried out in the presence of
various metal cations using 125 nM enzyme and 100 μM
L‐Glu-pNA.
Substrate proﬁling was achieved by the use of a
ﬂuorigenic substrate library containing 60 amino acids.26§http://proteinexpress.med.monash.eud.au/index.
htm
∥Available at www.analyticalultracentrifugation.comFor convenience in solid-phase synthesis, we employed a
7-amino-4-carbamoylmethylcoumarin (ACC) ﬂuorogenic
leaving group in this library. Final screening of the library
was carried out at 5 μM substrate and 120 nM enzyme as
described above and release of free ACC ﬂuorophore was
monitored. The substrate concentration ranged from 10 to
1600 μM to measure the Km values of the selected four
substrates. Each experiment was repeated at least three
times, and the average value with standard error was
calculated. The concentration of dimethyl sulfoxide in the
assay was less than 2% (v/v).Crystallization and X-ray data collection
Puriﬁed PfM18AAP enzyme was concentrated to
~9 mg/ml and crystals were grown using the hanging
drop vapor diffusion method, with 1:1 (v/v) ratio of
protein to mother liquor (0.5 ml well volume). The
crystals appeared in 67% (v/v) methyl‐2,4‐pentanediol.
Crystal morphology was very small cubes (typically
b0.015 mm) that did not diffract on in-house X-ray
sources or the macromolecular beamline (MX1) at the
Australian Synchrotron. Data were collected at 100 K
using the Micro Crystallography beamline (MX2) at the
Australian Synchrotron and typically required 5‐s expo-
sure of 100% ﬂux to achieve medium resolution. Data
sets were collected on crystals at the Zn K-peak and at
20 eV above and below the peak to evaluate active‐site
Zn occupancy.
Diffraction images were processed using MOSFLM,38
pointless,39 and SCALA39 from the CCP4 suite.40 Five
percent of each data set was ﬂagged for calculation of
Rfree
41 with neither a sigma nor a low-resolution cutoff
applied to the data. A summary of statistics is provided in
Table 3. Subsequent crystallographic and structural
analysis was performed using the CCP4i interface42 to
the CCP4 suite,40 unless stated otherwise.Structure determination and refinement
Structure determination proceeded using the molecu-
lar replacement method and the program PHASER.43 A
search model was constructed from the crystal structure
of DNPEP (Protein Data Bank ID: 3L6S) (probe
identiﬁed using the FFAS server44 ). A “mixed” model
consisting of conserved side chains (all other non‐
alanine/glycine residues truncated at Cγ atom) was
then created using the SCRWL server.44 Four clear peaks
in both the rotation and translation functions were
evident, and these packed well within the asymmetric
unit. Together with the unbiased features in the initial
electron density maps, the correctness of the molecular
replacement solution was conﬁrmed.
Initial structure reﬁnement and model building pro-
ceeded using one molecule in the asymmetric unit [with
the other noncrystallographic symmetry (NCS)-related
molecules generated using NCS operators]. Maximum
likelihood reﬁnement using AutoBuster,28 incorporating
translation, liberation, and screw-rotation displacement
(TLS) reﬁnement, was carried out. After initial Cα
backbone trace was completed for one chain, NCS
restraints were reduced to identical molecules in each
hexamer and retained throughout to improve observation
506 Crystal Structure and Specificity of PfM18AAPto parameter ratio. When restraints were relaxed, no
change in electron density was noted. Simulated anneal-
ing composite omit maps were generated using CNS45
omitting 5% of the model. All model building and
structural validation were performed using Coot.27
Solvent molecules were added only if they had acceptable
hydrogen-bonding geometry contacts of 2.5 to 3.5 Å with
protein atoms or with existing solvent and were in good
2Fo−Fc and Fo−Fc electron density.
PyMOL was used to produce all structural representa-
tions¶. Hydrogen bonds (excluding water-mediated
bonds) and salt bridges were calculated using
PDBePISA.46 The coordinates and structure factors are
available from the Protein Data Bank (4EME). Raw data
and images are available from TARDISa.47Acknowledgements
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